Graff on Using the Signatera Assay to Assess ctDNA in Early Breast Cancer

Stephanie L. Graff, MD, director, breast oncology, Lifespan Cancer Institute, assistant professor of medicine, Warren Alpert Medical School, co-leader, Breast Cancer Translational Research Disease Group, Brown University’s Legorreta Cancer Center, discusses what a community oncologist should know about her presentation on the Signatera^TM assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib (Verzenio) and endocrine therapy which was given at the 2023 San Antonio Breast Cancer Symposium.

This was a pilot study which examined the association between disease recurrence and circulating tumor DNA (ctDNA) positivity of this patient population by using the Signatera™ assay in a subset of patients from the phase 3 monarchE trial (NCT03155997).

Transcription

0:09 | I think that as a community oncologist, your patient is very likely to come and say, hey, I read about Signatera^TM ctDNA at San Antonio Breast in my Facebook group or on the news, etc. And I think it's important to know, again, this is a pilot study. It is a very enriched patient population for those [invasive disease-free survival] events in limited time points, and so not practice changing. This is not something that I'm offering my patients every day in the clinic, this is something that I'm utilizing in a clinical trial in a very different setting.

0:52 | And so I think that distinguishing the difference between everyday clinical practice and routine clinical care are just different settings and making sure that we do not complicate care with data that's not ready to change the way that we practice yet is key.